WestminsterResearch

Anandamide and noladin ether prevent neurotoxicity of the human amyloid-ß peptide

Milton, Nathaniel G.N. (2002) Anandamide and noladin ether prevent neurotoxicity of the human amyloid-ß peptide. Neuroscience Letters, 332 (2). pp. 127-130. ISSN 0304-3940

Full text not available from this repository.

Official URL: http://dx.doi.org/10.1016/S0304-3940(02)00936-9

Abstract

Cannabinoid receptor agonists including anandamide and noladin either have recently been suggested to exhibit neuroprotective properties. The amyloid-β (Aβ) peptide is thought to be responsible for the neurodegenerative changes associated with Alzheimer's disease pathology. This study characterizes the effects of anandamide and noladin ether on the neurotoxicity of Aβ in differentiated human teratocarcinoma cell line, Ntera 2/cl-D1 neurons. Anandamide and noladin ether, at nanomolar concentrations, showed concentration dependent inhibition of Aβ toxicity. A CB1 cannabinoid receptor antagonist, AM251, prevented the protective effects of anandamide and noladin ether. The mitogen activated protein kinase (MAPK) pathway inhibitor PD98059 also prevented the protective effects of cannabinoids and corticotrophin-releasing hormone. These results suggest that activation of the MAPK pathway by either cannabinoids or corticotrophin-releasing hormone could be used to prevent Aβ peptide induced neurodegeneration.

Item Type:Article
Research Community:University of Westminster > Life Sciences, School of
ID Code:7378
Deposited On:26 Jan 2010 15:29
Last Modified:26 Jan 2010 15:29

Repository Staff Only: item control page